Table of Contents
Hepatitis Research and Treatment
Volume 2010, Article ID 901216, 9 pages
Review Article

Can Engineered “Designer” T Cells Outsmart Chronic Hepatitis B?

1Institut für Virologie, Technische Universität München/Helmholtz Zentrum München, 81675 München, Germany
2Zentrum für Molekulare Medizin Köln und Klinik I für Innere Medizin Köln, Universität zu Köln, Robert-Koch-Str. 21, 50931 Köln, Germany

Received 27 May 2010; Revised 14 July 2010; Accepted 15 July 2010

Academic Editor: Alfred M. Prince

Copyright © 2010 U. Protzer and H. Abken. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More than 350 million people worldwide are persistently infected with human heptatitis B virus (HBV) and at risk to develop liver cirrhosis and hepatocellular carcinoma making long-term treatment necessary. While a vaccine is available and new antiviral drugs are being developed, elimination of persistently infected cells is still a major issue. Recent efforts in adoptive cell therapy are experimentally exploring immunotherapeutic elimination of HBV-infected cells by means of a biological attack with genetically engineered “designer” T cells.